General
Preferred name
ETOPOSIDE
Synonyms
VP-16 ()
VP-16-213 ()
Etoposide (VP-16) ()
VP-16213,Vepesid,VP-16 ()
Etoposide?(VP-16) ()
Toposar ()
Sintopozid ()
Etoposide resolution mixture ()
Etoposido ()
NSC-141540 ()
VePesid ()
Etoposidum ()
Etoposide-d3 ()
P&D ID
PD003202
CAS
33419-42-0
121471-01-0
Tags
available
drug
nuisance
Approved by
PMDA
FDA
First approval
1983
Drug indication
acute lymphoblastic leukemia
Solid tumour/cancer
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION A DNA topoisomerase II inhibitor which is a synthetic derivative of podophyllotoxin, found in the American Mayapple (Podophyllum peltatum). (GtoPdb)
DESCRIPTION Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].
PRICE 29
DESCRIPTION Etoposide (VP-16-213) is a topoisomerase II inhibitor that inhibits DNA synthesis by forming a complex with topoisomerase II and DNA (IC50=60.3 ??M). Etoposide has antitumor activity and induces apoptosis and autophagy.
DESCRIPTION inhibitor of topoisomerase II (Informer Set)
DESCRIPTION Protein kinase inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Topoisomerase II inhibitor (Tocriscreen Plus)
DESCRIPTION Etoposide is a podophyllotoxin derivative used to treat testicular and small cell lung tumors. (Enamine Bioactive Compounds)
DESCRIPTION Etoposide (VP-16-213) is a topoisomerase II inhibitor that inhibits DNA synthesis by forming a complex with topoisomerase II and DNA (IC50=60.3 μM). Etoposide has antitumor activity and induces apoptosis and autophagy. (TargetMol Bioactive Compound Library)
Cell lines
691
Organisms
3
Compound Sets
35
A Collection of Useful Nuisance Compounds (CONS) for Interrogation of Bioassay Integrity
AdooQ Bioactive Compound Library
A10373
Cayman Chemical Bioactives
12092
26488
ChEMBL Approved Drugs
CHEMBL44657
ChEMBL Drugs
CHEMBL44657
Concise Guide to Pharmacology 2017/18
6815
Concise Guide to Pharmacology 2019/20
6815
Concise Guide to Pharmacology 2021/22
6815
Concise Guide to Pharmacology 2023/24
6815
Drug Repurposing Hub
DrugBank
DB00773
DrugBank Approved Drugs
DB00773
DrugCentral
1112
DrugCentral Approved Drugs
1112
DrugMAP
DMNH3PG
DrugMAP Approved Drugs
DMNH3PG
Enamine Bioactive Compounds
EBC-11154
EU-OPENSCREEN Bioactive Compound Library
EOS100660
Guide to Pharmacology
6815
Informer Set
48589
LINCS compound set
10250-101
10250-999
MedChem Express Bioactive Compound Library
HY-13629
NCATS Inxight Approved Drugs
6PLQ3CP4P3
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
Selleckchem Bioactive Compound Library
Etopophos
TargetMol Bioactive Compound Library
T0132
Tocris Bioactive Compound Library
1226
Tocriscreen Plus
1226
Welcome Trust Cancer Drugs
134
External IDs
60
Properties
(calculated by RDKit )
Molecular Weight
588.18
Hydrogen Bond Acceptors
13
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
7
Aromatic Ring Count
2
cLogP
1.34
TPSA
160.83
Fraction CSP3
0.55
Chiral centers
10.0
Largest ring
6.0
QED
0.43
Structural alerts
1
Genotoxic
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target
TOP2A
TOP2
TOP2A, TOP2B
antibiotic
Bacterial
Mitophagy
Antineoplastic and Immunosuppressive Antibiotics,Apoptosis related,Autophagy,Mitophagy,Topoisomerase
Topo II
Compound status
FDA
Target Type
Enzymes
Pathway
DNA replication
Apoptosis
Autophagy
DNA Damage/DNA Repair
Microbiology/virology
Anti-infection
Cell Cycle/DNA Damage
Primary Target
DNA Topoisomerases
MOA
Inhibitor
Topoisomerase
Topoisomerase II inhibitor
Tubulin modulator
"Topoisomerase II inhibitor
Tubulin modulator"
Topoisomerase inhibitor
Member status
member
Indication
non-small cell lung cancer (NSCLC)
Cellular injury category
Genotoxin
Therapeutic Class
Anticancer Agents
Nuisance MOA
Genotoxic
Targets
Topoisomerase II
Source data